AUTL
AUTOLUS THERAPEUTICS PLC
$2.06
Earnings Summary
Revenue | $0.68Mn |
Net Profits | $-37.32Mn |
Net Profit Margins | -5487.5% |
Highlights
AUTOLUS THERAPEUTICS PLC’s revenue jumped 128.96% since last year same period to $0.68Mn in the Q3 2020. On a quarterly growth basis, AUTOLUS THERAPEUTICS PLC has generated 132.08% jump in its revenue since last 3-months.
AUTOLUS THERAPEUTICS PLC’s net profit fell -36.95% since last year same period to $-37.32Mn in the Q3 2020. On a quarterly growth basis, AUTOLUS THERAPEUTICS PLC has generated -16.45% fall in its net profits since last 3-months.
AUTOLUS THERAPEUTICS PLC’s net profit margin jumped 40.19% since last year same period to -5487.5% in the Q3 2020. On a quarterly growth basis, AUTOLUS THERAPEUTICS PLC has generated 49.83% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the AUTOLUS THERAPEUTICS PLC post its latest quarter earnings
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Current Year | -0.4 |
Highlights
AUTOLUS THERAPEUTICS PLC’s earning per share (EPS) estimates for the current quarter stand at -0.4 - a 12.12% jump from last quarter’s estimates.
AUTOLUS THERAPEUTICS PLC’s earning per share (EPS) estimates for the current year stand at -0.4.
Key Ratios
Key ratios of the AUTOLUS THERAPEUTICS PLC post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
AUTOLUS THERAPEUTICS PLC’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the AUTOLUS THERAPEUTICS PLC has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2021-12-31 | -0.46 | -0.51 | -10.87% |
2021-03-31 | -0.6 | -0.53 | 11.67% |
2021-06-30 | -0.5 | -0.47 | 6% |
2021-09-30 | -0.51 | -0.47 | 7.84% |
Company Information
Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Organisation | AUTOLUS THERAPEUTICS PLC |
Headquarters | The MediaWorks, London, United Kingdom, W12 7FP |
Employees | 399 |
Industry | Health Technology |
Discover More Earning Stocks in Health Technology Sector
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*